GenoLogics and CLC bio to Provide End-to-End Genomics Informatics and Analysis for Next Generation Sequencing
News Nov 05, 2009
GenoLogics and CLC bio has announced they will provide an end-to-end informatics and analysis solution, optimized for Next Generation Sequencing research that addresses both lab and data management and data analysis all within one integrated system.
This end-to-end solution will impact researchers’ ability to aggregate raw data across Next Generation Sequencing experiments to get to biological meaningful results faster. From initial sample submission to final analysis, GenoLogics’ lab and data management system for genomics, Geneus, and CLC bio’s CLC Genomics Server, CLC Genomics Workbench and CLC NGS Cell integrate seamlessly to help researchers get the most out of their Next Generation Sequencing instruments.
Thomas Knudsen, CEO at CLC bio, states, “With this collaboration, our Enterprise Platform expands with an end-to-end workflow that couples world-class LIMS functionalities like tracking of samples and data as well as reporting, with our comprehensive Next Generation Sequencing analysis capabilities, to the obvious benefit of our customers. This way researchers can keep up with the vast volumes of sequencing data being churned out by high-throughput sequencing machines, and quickly turn the massive amounts of raw data into meaningful results.”
Sal Sanci, Vice President Products for GenoLogics, continues “We continually strive to provide our customers with solutions that marry best-in-class analytics tools and informatics to accelerate the path to meaningful results and discovery. This collaboration combines two proven systems, into one unified environment for data management and comprehensive analysis. We know our customers need a unified end-to-end solution and have asked for an integration between Geneus and CLC bio’s NGS platform – and now it’s available!”
Combined, these two systems offer a solution to researchers using next generation sequencing instruments. Researchers can keep pace with the growing volume of sequence data, and turn massive amounts of raw data into meaningful results.
This informatics and analysis solution offers researchers extensive sample tracking, project, and workflow management capabilities, as well as streamlined data pipelining, and comprehensive results analysis. Furthermore it provides users with a well organized and intuitive graphical interface for carrying out an extensive range of high-performance computing accelerated analyses within genomics, transcriptomics, and epigenomics.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.